News Release Details

SAN FRANCISCO, CA / ACCESSWIRE / November 9, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, have been accepted for presentation at the December 2023 San Antonio Breast Cancer Symposium (SABCS).

"We are delighted our breast cancer related survey results have been accepted for presentation at SABCS," said Advocates for Collaborative Education founder Stacey Tinianov, MPH. "While cancer treatments have advanced considerably since the advent and availability of targeted therapies, significant short- and long-term treatment side effects can be challenging or even devastating to an individual's quality of life. Our goal was to move beyond progression-free survival (PFS) and overall survival (OS) statistics to quantify quality-of-life impacts across a large sampling of individuals with a diagnosis or history of cancer. We were thrilled to have Napo's support and hope these findings will inform research, clinical care, and the broader cancer community on what matters most to individuals and, potentially, how best to address quality-of-life impacts through improvements in supportive care."

"Jaguar was delighted to provide fiscal support for this survey. We are deeply committed to supporting the dignity and quality of life of cancer patients and their ability to stay on their prescribed cancer treatment so they can achieve an optimal outcome," said Lisa Conte, Jaguar's president and CEO. "We acknowledge the rigors of both short-term and perpetual treatment and do not believe any cancer therapy-related side effect, whether it is extreme fatigue, debilitating diarrhea, chronic pain, or others, should ever be viewed as ‘acceptable' or ‘tolerable.'"

The survey received more than 500 responses and will offer a unique perspective on the experiences and priorities of those affected by cancer. Only the breast cancer related responses will be presented at SABCS, with the remainder of the results to be shared at subsequent oncology symposia and conferences.

Advocates for Collaborative Education co-created the survey with patients and survivors to design relevant questions whose answers may help the cancer ecosystem better understand the far-reaching impacts of a cancer diagnosis and treatment on quality of life. The results of this study are poised to transform the way we approach cancer care and support, potentially addressing not only the clinical aspects but also the physical, emotional, social, financial, and psychological impacts on those affected by this relentless disease.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that results of the quality of life study will be presented at SABCS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.